The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim.

被引：0
|
作者：
Jones, S. [1 ]
Paul, D. [1 ]
Sedlacek, S. [1 ]
Vukelja, S. [1 ]
Wilks, S. T. [1 ]
Stokoe, C. [1 ]
Osborne, C. R. [1 ]
Krekow, L. [1 ]
McIntyre, K. [1 ]
Holmes, F. A. [1 ]
Guerra, L. [1 ]
Zhan, F. [1 ]
Asmar, L. [1 ]
O'Shaughnessy, J. [1 ]
Blum, J. L. [1 ]
机构：
[1] US Oncol, The Woodlands, TX USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-18-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-09
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophospliamide (TC) chemotherapy for early breast cancer
    Lakhanpal, Roopa
    Stuart-Harris, Robin
    Chan, Arlene
    Kotasek, Dusan
    Beith, Jane McNeil
    Cuff, Katharine
    Bastick, Patricia A.
    Lee, Clara Inkyung
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Febrile neutropenia and primary prophylactics in docetaxel plus cyclophosphamide chemotherapy for breast cancer: A Japanese institution experience
    Kimura, Y.
    Sasada, S.
    Goda, N.
    Emi, A.
    Kajitani, K.
    Masumoto, N.
    Haruta, R.
    Kadoya, T.
    Kataoka, T.
    Okada, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Incidence of febrile neutropenia (FN) is not altered by the day of administration of pegfilgrastim (PEG)
    Athar, U.
    Rajan, A.
    Gajra, A.
    Lynch, T. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Incidence of febrile neutropenia in docetaxel chemotherapy without prophylactic granulocyte-colony stimulating factor (GCSF) for metastatic prostate cancer
    Renninson, Emily
    Closier, Philippa
    Jonnada, Sai
    CLINICAL ONCOLOGY, 2018, 30 : E1 - E1
  • [25] Incidence of febrile neutropenia in docetaxel chemotherapy without prophylactic granulocyte-colony stimulating factor (GCSF) for metastatic prostate cancer
    Renninson, Emily
    Closier, Philippa
    Jonnada, Sai
    CLINICAL ONCOLOGY, 2018, 30 : E4 - E4
  • [26] COST EFFECTIVENESS OF PEGFILGRASTIM FOR REDUCING INCIDENCE OF FEBRILE NEUTROPENIA EVENTS AFTER CYTOTOXIC CHEMOTHERAPY FOR SOLID TUMORS IN TURKEY
    Saka, G.
    Villa, G.
    Worth, G.
    Barron, R.
    Malhan, S.
    Lyman, G. H.
    VALUE IN HEALTH, 2016, 19 (03) : A151 - A151
  • [27] Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis
    Vandenberg, T.
    Younus, J.
    Al-Khayyat, S.
    CURRENT ONCOLOGY, 2010, 17 (02) : 56 - 57
  • [28] Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis
    Younus, J.
    Vandenberg, T.
    Jawaid, M.
    Jawaid, M. A.
    CURRENT ONCOLOGY, 2012, 19 (06) : 332 - 334
  • [29] The incidence of febrile neutropenia (FN) for chemotherapy patients receiving pegfilgrastim by an on-body injector (pegfilgrastim OBI) versus other FN prophylaxis strategies
    Mahtani, Reshma
    Crawford, Jeffrey
    Rifkin, Robert
    Dale, David
    Brookhart, Alan
    Gawade, Prasad
    Lawrence, Tatiana
    Balani, Rejesh
    Lyman, Gary H.
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
    Yoshimasa Kosaka
    Yoshiaki Rai
    Norikazu Masuda
    Toshimi Takano
    Toshiaki Saeki
    Seigo Nakamura
    Ryutaro Shimazaki
    Yoshinori Ito
    Yutaka Tokuda
    Kazuo Tamura
    Supportive Care in Cancer, 2015, 23 : 1137 - 1143
12345